Steven A. Rosenberg, M.D., Ph.D.
Dr. Rosenberg pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients.
As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3940
Bethesda, MD 20892-1201
Ph: 240-858-3080
SAR@nih.gov
-
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0074Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0049Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Open - RecruitingNCI Protocol ID NCI-17-C-0177Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Open - RecruitingNCI Protocol ID NCI-16-C-0027Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Open - RecruitingNCI Protocol ID NCI-14-C-0052Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
Open - RecruitingNCI Protocol ID NCI-14-C-0022Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
Open - RecruitingNCI Protocol ID NCI-13-C-0214Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-Mesothelin Gene Engineered Lymphocytes#xD;
Open - RecruitingNCI Protocol ID NCI-12-C-0111Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Safety and Feasibility of Administering T-Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII#xD;
Open - RecruitingNCI Protocol ID NCI-11-C-0266Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab at Time of Progression
Open - RecruitingNCI Protocol ID NCI-10-C-0166Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Follow up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies
Open - RecruitingNCI Protocol ID NCI-09-C-0161Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Evaluation for NCI Surgery Branch Clinical Research Protocols
Open - RecruitingNCI Protocol ID NCI-99-C-0128Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Selected Key Publications
- Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
- N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
- Science. 344: 641-5, 2014. [ Journal Article ]
- Nat Med. 19: 747-752, 2013. [ Journal Article ]
- Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
| Name | Position |
|---|---|
| Mary Black | Biologist |
| Ellen Bodurian R.N., B.S.N. | Research Nurse |
| Eugene S. Bond | Contractor |
| Colleen E. Buckley R.N. | Research Nurse Specialist |
| Gal Cafri Ph.D. | Postdoctoral Fellow (Visiting) |
| Xuemei (Sherry) Chen R.N. | Research Nurse |
| Harshini Chinnasamy | Biologist |
| Melissa A. Corbitt | IT Specialist |
| David N. Danforth Jr., M.S., M.D. | Staff Clinician |
| Drew Deniger Ph.D. | Postdoctoral Fellow (CRTA) |
| Monica Epstein R.N., B.S.N., O.C.N. | Research Nurse Specialist |
| Brittany L. Garr-Colon M.P.H., CCRP | Protocol Coordinator (Contr.) |
| Stephanie L. Goff, M.D. | Staff Clinician |
| Hyuni K. Halas Ph.D. | Contractor |
| Vid Leko M.D. | Clinical Fellow |
| Mary Link R.N. | Research Nurse Specialist |
| Frank J. Lowery Ph.D. | Research Fellow |
| Yong-Chen (William) Lu Ph.D. | Staff Scientist |
| Parisa Malekzadeh M.D. | Clinical Fellow |
| Deepti Jillella Marshall | Patient Care Coordinator (Contr.) |
| Christine T. McGowan R.N. | Research Nurse Specialist |
| Lori S. McIntyre R.N., B.S.N. | Research Nurse Specialist |
| Lien T. Ngo | Technical Laboratory Manager |
| Jennifer A. Pappas M.H.S. | Regulatory Affairs Manager (Contr.) |
| Biman C. Paria Ph.D. | Biologist |
| Sarah C. Ramirez R.N., B.S.N. | Research Nurse Specialist |
| Satyajit Ray Ph.D. | Biologist |
| Nicole Sellers | Contractor |
| Richard M. Sherry, M.D. | Staff Clinician |
| Margaret (Peggy) A. Shovlin R.N. | Research Nurse |
| Donald E. White | IT Specialist |
| Hui Xu | Biologist |
| Rami Yoseph Ph.D. | Postdoctoral Fellow (Visiting) |
| Jennifer V. Young R.N. | Research Nurse |
| Nikolaos Zacharakis Ph.D. | Research Fellow |
| Zhili Zheng | Biologist |
Clinical Trials
-
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0074Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0049Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Open - RecruitingNCI Protocol ID NCI-17-C-0177Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Open - RecruitingNCI Protocol ID NCI-16-C-0027Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Open - RecruitingNCI Protocol ID NCI-14-C-0052Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
Open - RecruitingNCI Protocol ID NCI-14-C-0022Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
Open - RecruitingNCI Protocol ID NCI-13-C-0214Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-Mesothelin Gene Engineered Lymphocytes#xD;
Open - RecruitingNCI Protocol ID NCI-12-C-0111Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Safety and Feasibility of Administering T-Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII#xD;
Open - RecruitingNCI Protocol ID NCI-11-C-0266Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab at Time of Progression
Open - RecruitingNCI Protocol ID NCI-10-C-0166Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Follow up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies
Open - RecruitingNCI Protocol ID NCI-09-C-0161Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Evaluation for NCI Surgery Branch Clinical Research Protocols
Open - RecruitingNCI Protocol ID NCI-99-C-0128Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505
Research
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Publications
Selected Key Publications
- Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
- N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
- Science. 344: 641-5, 2014. [ Journal Article ]
- Nat Med. 19: 747-752, 2013. [ Journal Article ]
- Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]
Biography
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Team
| Name | Position |
|---|---|
| Mary Black | Biologist |
| Ellen Bodurian R.N., B.S.N. | Research Nurse |
| Eugene S. Bond | Contractor |
| Colleen E. Buckley R.N. | Research Nurse Specialist |
| Gal Cafri Ph.D. | Postdoctoral Fellow (Visiting) |
| Xuemei (Sherry) Chen R.N. | Research Nurse |
| Harshini Chinnasamy | Biologist |
| Melissa A. Corbitt | IT Specialist |
| David N. Danforth Jr., M.S., M.D. | Staff Clinician |
| Drew Deniger Ph.D. | Postdoctoral Fellow (CRTA) |
| Monica Epstein R.N., B.S.N., O.C.N. | Research Nurse Specialist |
| Brittany L. Garr-Colon M.P.H., CCRP | Protocol Coordinator (Contr.) |
| Stephanie L. Goff, M.D. | Staff Clinician |
| Hyuni K. Halas Ph.D. | Contractor |
| Vid Leko M.D. | Clinical Fellow |
| Mary Link R.N. | Research Nurse Specialist |
| Frank J. Lowery Ph.D. | Research Fellow |
| Yong-Chen (William) Lu Ph.D. | Staff Scientist |
| Parisa Malekzadeh M.D. | Clinical Fellow |
| Deepti Jillella Marshall | Patient Care Coordinator (Contr.) |
| Christine T. McGowan R.N. | Research Nurse Specialist |
| Lori S. McIntyre R.N., B.S.N. | Research Nurse Specialist |
| Lien T. Ngo | Technical Laboratory Manager |
| Jennifer A. Pappas M.H.S. | Regulatory Affairs Manager (Contr.) |
| Biman C. Paria Ph.D. | Biologist |
| Sarah C. Ramirez R.N., B.S.N. | Research Nurse Specialist |
| Satyajit Ray Ph.D. | Biologist |
| Nicole Sellers | Contractor |
| Richard M. Sherry, M.D. | Staff Clinician |
| Margaret (Peggy) A. Shovlin R.N. | Research Nurse |
| Donald E. White | IT Specialist |
| Hui Xu | Biologist |
| Rami Yoseph Ph.D. | Postdoctoral Fellow (Visiting) |
| Jennifer V. Young R.N. | Research Nurse |
| Nikolaos Zacharakis Ph.D. | Research Fellow |
| Zhili Zheng | Biologist |
